THERAPY OF RECURRENT HEPATITIS C AFTER TRANSPLANTATION OF THE LIVER WITH DIRECT ACTING ANTI-HEPATITIS C VIRUS DRUGS: EXPERIENCE OF THREE RUSSIAN CENTERS


Cite item

Full Text

Abstract

The results of a retrospective analysis of the experience of three Russian regional liver transplantation centers in relation to antiviral therapy of recurrent hepatitis C in liver recipients are presented. There were studied six different therapeutic schedules with direct antiviral drugs (DAVD) administered in 91 patients. The frequency of the persistent virologic response in 12 weeks after the completion of therapy (PVR12) amounted to 92.3%. In recipients, the use of a combination of sofosbuvir and daclatasvir seems to be the most promising as following its administration relapses observed in only 3 out of the 57 recipients were associated with drug resistance mutations to NS5A inhibitors. There were no serious adverse events related to the use of DAVD. The frequency of the reactivation of HBV infection against the background of DAVD therapy in liver recipients did not exceed the previously reported frequency of de novo hepatitis B in non-endemic regions. In recurrent hepatitis C patients after the liver transplantation effects of both the virus genotype, the pronouncement of graft fibrosis and the addition of ribavirin, on the frequency of SVO12 have not been revealed.

About the authors

Vladimir E. Syutkin

N.V. Sklifosovsky Research Institute of First Aid

Email: vladsyutkin@gmail.com
MD, Ph.D., DSci., leading researcher of the N.V. Sklifosovsky Research Institute of First Aid, 3, bldg. 21, Bolshaya Sukharevskaya Square, Moscow, 129090, Russia 3, Bldg. 21, Bolshaya Sukharevskaya Square, 129090 Moscow, Russia

E. N Bessonova

Sverdlovsk Regional Clinical Hospital No 1, Sverdlovsk Regional Hepatology Center

Email: ben@okb1.ru
185, Volgogradskaya str., 620102 Ekaterinburg, Russia

M. N Davydenko

Professor S.V. Ochapovsky Research Institute - Regional Clinical Hospital No 1

Email: davidenkogastro@rambler.ru
167, 1 Maya str., 350901 Krasnodar, Russia

References

  1. Kim W.R., Smith J.M., Skeans M.A. et al. OPTN/SRTR 2012 Annual Data Report: liver. Am J Transplant, 2014. 14 Suppl 1: p. 69-96.
  2. Narang T.K., Ahrens W., and Russo M.W. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl, 2010. 16(11): 1228-35.
  3. Cholankeril G., March K., Yoo E. et al. The Declining Burden of HCV on the Liver Transplant Waitlist associated with the DAA era. Program and abstracts of the Best Pract Res Clin Haematol. 2017. HEPATOLOGY. 66(1 Suppl.): 72A
  4. Carrion J.A., Navasa M., Garcia-Retortillo M. et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology, 2007; 132(5): 1746-56.
  5. Belli L.S., Volpes R., Graziadei I. et al. Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study. Dig Liver Dis, 2012. 44(7): p. 603-609.
  6. HCV guidance: recommendations for testing, managing, and treating hepatitis C. Available from: http://www.hcvguidelines.org/full-report-view.
  7. Carrion J.A., Navasa M., Bosch J. et al. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl, 2006. 12(12): 1791-8.
  8. Zeuzem S., Dusheiko G.M., Salupere R. et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med, 2014. 370(21): p. 1993-2001.
  9. Charlton M., Gane E., Manns M.P. et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology, 2015. 148(1): 108-17.
  10. Kwo P.Y., Mantry P.S., Coakley E. et al. An Interferon-free Antiviral Regimen for HCV after Liver Transplantation. N Engl J Med, 2014. 371(25): 2375-82.
  11. Badri P.S., Parikh A., Coakley E.P. et al. Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. Therapeutic drug monitoring, 2016. 38(5): p. 640-5.
  12. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol, 2017. 66(1): 153-94.
  13. Manns M., Pol S., Jacobson I.M. et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet, 2014. 384(9954): p. 1597-605.
  14. Ishigami M., Hayashi K., Honda T. et al. Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93. J Med Virol, 2017.
  15. Omata M., Kanda T., Wei L. et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatology international, 2016. 10(5): p. 702-26.
  16. Nguyen N.H., Yee B.E., Chang C. et al. Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis. BMJ open gastroenterology, 2016. 3(1): p. e000066.
  17. Punzalan C.S., Barry C., Zacharias I. et al. Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant. Clin Transplant, 2015. 29(12): p. 1105-11.
  18. Saab S., Greenberg A., Li E. et al. Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients. Liver Int, 2015. 35(11): p. 2442-7.
  19. Nair S., Satapathy S.K., and Gonzalez H.C. Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant. Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation, 2016.
  20. Issa D., Eghtesad B., Zein N.N., et al., Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation. International journal of organ transplantation medicine, 2016. 7(1): p. 38-45.
  21. Ouwerkerk-Mahadevan S., Snoeys J., Peeters M. et al. Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir. Clinical pharmacokinetics, 2016. 55(2): 197-208.
  22. Charlton M., Everson G.T., Flamm S.L. et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology, 2015. 149(3): p. 649-59.
  23. Manns M., Samuel D., Gane E.J. et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis, 2016. 16(6): p. 685-97.
  24. Thompson A.J. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. The Medical journal of Australia, 2016. 204(7): 268-72.
  25. Poordad F., Schiff E.R., Vierling J.M. et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology, 2016. 63(5): p. 1493-505.
  26. Foster G.R., Irving W.L., Cheung M.C. et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol, 2016. 64(6): p. 1224-31.
  27. Coilly A., Fougerou-Leurent C., De Ledinghen V. et al. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence after liver transplantation - The CO23 ANRS CUPILT study. J Hepatol, 2016. 65(4): p. 711-8.
  28. Liao H., Tan P., Zhu Z. et al. Sofosbuvir in combination with daclatasvir in liver transplant recipients with HCV infection: A systematic review and meta-analysis. Clinics and research in hepatology and gastroenterology, 2017. 41(3): p. 262-71.
  29. Fontana R.J., Brown R.S., Jr., Moreno-Zamora A. et al. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl, 2016. 22(4): 446-58.
  30. Сюткин В.Е., Андрейцева О.И., Салиенко А.А. и др. Клинические варианты инфекции HBV у больных, перенесших трансплантацию печени. Вестник трансплантологии и искусственных органов, 2011(2): 37-45.
  31. Bersoff-Matcha S.J., Cao K., Jason M. et al. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann Intern Med, 2017. 166(11): 792-8.
  32. Takayama H., Sato T., Ikeda F. et al. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res, 2016. 46(5): 489-91.
  33. Wang C., Ji D., Chen J. et al. Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents. Clin Gastroenterol Hepatol, 2017. 15(1): 132-6.
  34. Kawagishi N., Suda G., Onozawa M. et al. Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C. J Viral Hepat, 2017. 24(12): 1098-106.
  35. Roche B., Samuel D., Gigou M. et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol, 1997. 26(3): 517-26.
  36. Castells L., Vargas V., Rodriguez F. et al. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transpl, 2002. 8(10): 892-900.
  37. Fabia R., Levy M.F., Crippin J. et al. De novo hepatitis B infection after liver transplantation: source of disease, incidence, and impact. Liver Transpl Surg, 1998. 4(2): 119-27.
  38. Moini M., Schilsky M.L., and Tichy E.M. Review on immunosuppression in liver transplantation. World J Hepatol, 2015. 7(10): 1355-68.
  39. Saxena V., Khungar V., Verna E.C. et al. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. Hepatology, 2017. 66(4): 1090-101.
  40. Saab S., Rheem J., Jimenez M. et al. Curing Hepatitis C in Liver Transplant Recipients Is Associated with Changes in Immunosuppressant Use. Journal of clinical and translational hepatology, 2016. 4(1): 32-8.

Copyright (c) 2018 Eco-vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies